Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06305247 · ClinicalTrials.gov registry record · Phase 1

A Study to Assess IPN01194 When Administered Alone in Adults With Advanced Solid Tumours

A Phase 1 study of Colorectal Cancer and Melanoma, sponsored by Ipsen.

Recruiting
Registry status
Phase 1
Development phase
220
Enrollment target
12
Study locations

NCT06305247 is a Phase 1 study of Colorectal Cancer and Melanoma that is actively recruiting participants, run by Ipsen. The registered enrollment target is 220 participants, below the 1,511-participant average among 369 other Colorectal Cancer trials with a reported enrollment target (85% lower). The trial reports 12 study locations across 5 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06305247, a Phase 1 study of Colorectal Cancer and Melanoma, is actively recruiting participants, sponsored by Ipsen.

RECRUITING
Registry status
Phase 1
Development phase
220 participants
Enrollment target
12
Study locations

Study Summary

The purpose of this study is to determine the appropriate dosage, safety and effectiveness of the study drug, IPN01194 in adults with advanced solid tumours. The participants in this study will have advanced solid tumours. 'Advanced solid tumours' refers to cancers that can occur in several places, including cancers in organs or tissues that have spread from their original site to nearby tissues or other parts of the body. In this study, all participants will receive the study drug, which will be taken by mouth (orally).

Conditions Studied

Colorectal Cancer Melanoma Solid Tumor Head and Neck Squamous Cell Carcinoma Pancreatic Ductal Adenocarcinoma

Interventions

  • DRUG IPN01194

Study Locations (12)

Other

  • Centre Léon Bérard - Lyon - Lyon
  • Paris Saint-Louis - Paris
  • Institut de Cancerologie de l'Ouest (St-Herblain) - Saint-Herblain
  • IGR-Villejuif - Villejuif
  • Barcelona - Val D'Hebron - Barcelona
  • Fundacion Jimenez Diaz - Madrid - Madrid
  • M.D. Anderson Cancer Center Madrid - Madrid

California

  • The Angeles Clinic and Research Institute - California - Los Angeles
  • UC San Diego Health System - La Jolla - San Diego

Connecticut

  • Yale Cancer Center - New Heaven - New Haven

Tennessee

  • Sarah Cannon Research Institute (SCRI) - Nashville - Nashville

Virginia

  • Virginia Cancer Specialist - Fairfax

Trial Details

FieldValue
Enrollment Target 220 participants
Start Date 2024-04-03
Est. Completion 2028-03-20
Phase Phase 1

Sponsor

Ipsen

85 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06305247

The ClinicalTrials.gov registry entry for NCT06305247 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 220 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,511-participant average among 369 other Colorectal Cancer trials with a reported enrollment target (85% lower). The listed sponsor is Ipsen, which has 85 total studies on file at ClinicalTrials.gov.

The record links to 5 conditions, with Colorectal Cancer appearing as the primary indexed condition, and to 1 intervention - of which IPN01194 is the first listed.

NCT06305247 reports 12 study locations spanning 5 distinct geographic areas - top geographies include Other, California, Connecticut.

Frequently Asked Questions

What is clinical trial NCT06305247 about?

NCT06305247 is a clinical study titled "A Study to Assess IPN01194 When Administered Alone in Adults With Advanced Solid Tumours". The purpose of this study is to determine the appropriate dosage, safety and effectiveness of the study drug, IPN01194 in adults with advanced solid tumours. The participants in this study will have advanced solid tumours. 'Advanced solid tumours' refers to cancers that can occur in several places,...

What is the current status of trial NCT06305247?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 220 participants. The study started on 2024-04-03. Estimated completion is 2028-03-20.

What conditions does trial NCT06305247 study?

This clinical trial studies the following conditions: Colorectal Cancer, Melanoma, Solid Tumor, Head and Neck Squamous Cell Carcinoma, Pancreatic Ductal Adenocarcinoma.

What interventions are being tested in trial NCT06305247?

The interventions under investigation include: IPN01194 (DRUG).

Who is sponsoring clinical trial NCT06305247?

This trial is sponsored by Ipsen, which has 85 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06305247 being conducted?

This trial has 12 study locations across California, Connecticut, Tennessee, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Colorectal Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Colorectal Cancer

All registered trials for this condition

Melanoma

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.